( LEXINGTON Mass.--(BUSINESS WIRE)--Jun ...)EPIX Pharmaceuticals Presents Findings from PRX-00023 Phase 3,Clinical Trial at 47th Annual NCDEU Meeting,Health

LEXINGTON, Mass.--(BUSINESS WIRE)--Jun 13, 2007 - EPIX Pharmaceuticals, Inc. (NASDAQ: EPIX) today announced that data from its Phase 3 trial of PRX-00023, a novel long-acting 5-HT1A agonist, was featured in a poster presentation at the 47th Annual New Clinical Drug Evaluation Unit (NCDEU) Meeting in Boca Raton, Florida. The meeting is sponsored by the National Institutes of Health and the American Society of Clinical Psychopharmacology.

The presentation highlighted data from a randomized, double-blind, placebo-controlled Phase 3 study of PRX-00023 in 311 patients with generalized anxiety disorder (GAD). Top-line results from the trial were announced in September 2006. The primary endpoint of the trial was change from baseline in the Hamilton Rating Scale for Anxiety (HAM-A). PRX-00023 showed a trend (p=0.116) to reduce the level of anxiety versus placebo based on the HAM-A; data from the trial also indicated a statistically significant change in the Montgomery Asberg Depression Rating Scale (MADRS), with p=0.0094. The MADRS measures symptoms of depression and was a pre-specified secondary endpoint in this trial. Results also indicated that PRX-00023 was well-tolerated, there was a low rate of discontinuation due to adverse events and side effects seen were similar to placebo, including impact on sexual function and sleep.

"Although PRX-00023 did not meet the primary endpoint in this Phase 3 trial, we were pleased by our secondary endpoint results - statistically significant MADRS data," said Michael G. Kauffman, M.D., Ph.D., chief executive officer of EPIX. "The MADRS results encouraged us to accelerate our clinical plans for PRX-00023 in major depression. We look forward to the results of our ongoing depression trial in the first half of next year."

In March 2007, EPIX announced the initiation of a randomized, double-blind, placebo-controlled Phase 2b trial in 330 patients with major depressive d
'"/>

Page: 1 2 3 4
Related medicine technology :

1. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
2. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
4. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
5. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
6. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
7. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
10. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
11. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA